SCHEMBL26100452

SCHEMBL26100452

CCCCN1CCc2nc3ccccc3c(C(=O)Nc3ccc(F)c(F)c3)c2C1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.64
▸ LMNA P02545 4/20 0.51
▸ GAA P10253 2/20 0.51
▸ ALDH1A1 P00352 8/20 0.51
▸ TP53 P04637 2/20 0.51
▸ KMT2A Q03164 5/20 0.49
▸ POLB P06746 5/20 0.49
▸ L3MBTL1 Q9Y468 3/20 0.49
▸ HTT P42858 2/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ MEN1 O00255 4/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ RECQL P46063 2/20 0.46
▸ BLM P54132 1/20 0.44
▸ MCL1 Q07820 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26100469 0.92 MAPT (0.60) MAPTLMNAGAAALDH1A1TP53
SCHEMBL26099168 0.91 MAPT (0.76) MAPTLMNAGAAALDH1A1TP53
SCHEMBL26097470 0.91 MAPT (0.61) MAPTLMNAGAAALDH1A1TP53
SCHEMBL26099007 0.91 MAPT (0.59) MAPTLMNAGAAALDH1A1TP53
SCHEMBL26099897 0.90 MAPT (0.61) MAPTLMNAGAAALDH1A1TP53
SCHEMBL26096141 0.90 MAPT (0.61) MAPTLMNAGAAALDH1A1TP53
SCHEMBL26100890 0.90 MAPT (0.57) MAPTLMNAGAAALDH1A1TP53
SCHEMBL26100273 0.90 MAPT (0.61) MAPTLMNAGAAALDH1A1TP53
SCHEMBL26099460 0.89 MAPT (0.60) MAPTLMNAGAAALDH1A1TP53
SCHEMBL26098359 0.89 MAPT (0.60) MAPTLMNAGAAALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12370183-B2 Compositions and methods for treating malaria RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2025-07-29 — — US disclosed
US-20230139910-A1 COMPOSITIONS AND METHODS FOR TREATING MALARIA UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2023-05-04 — — US disclosed
US-20230139910-A1 COMPOSITIONS AND METHODS FOR TREATING MALARIA UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2023-05-04 — — US disclosed
US-20230139910-A1 COMPOSITIONS AND METHODS FOR TREATING MALARIA UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2023-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12370183-B2 Compositions and methods for treating malaria G6PD, QDPR, FASN MAPT 1034/4885LMNA 969/4885GAA 269/4885
US-20230139910-A1 COMPOSITIONS AND METHODS FOR TREATING MALARIA G6PD, QDPR, FASN MAPT 1034/4885LMNA 969/4885GAA 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback